92 related articles for article (PubMed ID: 10679990)
1. Location of alkali metal binding sites in endothelin A selective receptor antagonists, cyclo(D-Trp-D-Asp-Pro-D-Val-Leu) and cyclo(D-Trp-D-Asp-Pro-D-Ile-Leu), from multistep collisionally activated decompositions.
Ngoka LC; Gross ML
J Mass Spectrom; 2000 Feb; 35(2):265-76. PubMed ID: 10679990
[TBL] [Abstract][Full Text] [Related]
2. Novel sodium binding properties of some cyclopentapeptide endothelin A selective receptor antagonists: electrospray and fast-atom-bombardment mass spectrometric studies.
Ngoka LC; Gross ML
Biochem Biophys Res Commun; 1999 Jan; 254(3):713-9. PubMed ID: 9920807
[TBL] [Abstract][Full Text] [Related]
3. Endothelin (ET)-1-induced inhibition of ATP release from PC-12 cells is mediated by the ETB receptor: differential response to ET-1 on ATP, neuropeptide Y, and dopamine levels.
Gardner A; Westfall TC; Macarthur H
J Pharmacol Exp Ther; 2005 Jun; 313(3):1109-17. PubMed ID: 15687374
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the structures of the endothelin A receptor antagonists BQ123 and N-methyl leucine BQ123 with the crystal structure of the C-terminal tail of endothelin-1.
Peishoff CE; Janes RW; Wallace BA
FEBS Lett; 1995 Nov; 374(3):379-83. PubMed ID: 7589575
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of human endothelin receptors ETA and ETB identification of regions involved in the selectivity for endothelin 3 or cyclo-(D-Trp-D-Asp-Pro-D-Val-Leu).
Becker A; Haendler B; Hechler U; Schleuning WD
Eur J Biochem; 1994 May; 221(3):951-8. PubMed ID: 8181477
[TBL] [Abstract][Full Text] [Related]
6. Multistep tandem mass spectrometry for sequencing cyclic peptides in an ion-trap mass spectrometer.
Ngoka LC; Gross ML
J Am Soc Mass Spectrom; 1999 Aug; 10(8):732-46. PubMed ID: 10439511
[TBL] [Abstract][Full Text] [Related]
7. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide.
Dutta AS; Crowther M; Gormley JJ; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Jamieson A; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
J Pept Sci; 2000 Jul; 6(7):321-41. PubMed ID: 10946997
[TBL] [Abstract][Full Text] [Related]
8. Caged and clustered structures of endothelin inhibitor BQ123, cyclo(-D-Trp-D-Asp--Pro-D-Val-Leu-)-Na+, forming five and six coordination bonds between sodium ions and peptides.
Doi M; Asano A; Ishida T; Katsuya Y; Mezaki Y; Sasaki M; Terashima A; Taniguchi T; Hasegawa H; Shiono M
Acta Crystallogr D Biol Crystallogr; 2001 May; 57(Pt 5):628-34. PubMed ID: 11320303
[TBL] [Abstract][Full Text] [Related]
9. Endothelin-1-evoked calcium transients in UMR-106 osteoblastic osteosarcoma cells are mediated through endothelin-A and endothelin-B receptors.
Semler DE; Ohlstein EH; Nambi P; Slater C; Stern PH
J Pharmacol Exp Ther; 1995 Mar; 272(3):1052-8. PubMed ID: 7891315
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and conformational analysis of cyclic pentapeptide endothelin antagonists.
Lin M; Chan MF; Balaji VN; Castillo RS; Larive CK
Int J Pept Protein Res; 1996 Sep; 48(3):229-39. PubMed ID: 8897090
[TBL] [Abstract][Full Text] [Related]
11. Multi-stage collisionally-activated decomposition in an ion trap for identification of sequences, structures and bn --> bn-1 fragmentation pathways of protonated cyclic peptides.
Jia C; Qi W; He Z; Qiao B
Eur J Mass Spectrom (Chichester); 2006; 12(4):235-45. PubMed ID: 17057280
[TBL] [Abstract][Full Text] [Related]
12. Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties.
Cody WL; He JX; Reily MD; Haleen SJ; Walker DM; Reyner EL; Stewart BH; Doherty AM
J Med Chem; 1997 Jul; 40(14):2228-40. PubMed ID: 9216842
[TBL] [Abstract][Full Text] [Related]
13. Endothelin-induced nociception in mice: mediation by ETA and ETB receptors.
Raffa RB; Schupsky JJ; Jacoby HI
J Pharmacol Exp Ther; 1996 Feb; 276(2):647-51. PubMed ID: 8632332
[TBL] [Abstract][Full Text] [Related]
14. Cyclization reaction of peptide fragment ions during multistage collisionally activated decomposition: an inducement to lose internal amino-acid residues.
Jia C; Qi W; He Z
J Am Soc Mass Spectrom; 2007 Apr; 18(4):663-78. PubMed ID: 17234429
[TBL] [Abstract][Full Text] [Related]
15. Conformational study of cyclo[D-Trp-D-Asp-Pro-D-Val-Leu], an endothelin-A receptor-selective antagonist.
Atkinson RA; Pelton JT
FEBS Lett; 1992 Jan; 296(1):1-6. PubMed ID: 1309703
[TBL] [Abstract][Full Text] [Related]
16. Rediscovering an endothelin antagonist (BQ-123): a self-deconvoluting cyclic pentapeptide library.
Spatola AF; Crozet Y
J Med Chem; 1996 Sep; 39(19):3842-6. PubMed ID: 8809172
[TBL] [Abstract][Full Text] [Related]
17. Potent cyclic peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation.
Dutta AS; Gormley JJ; Coath M; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Ferguson R; Halterman T; Jamieson A; Moors JA; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
J Pept Sci; 2000 Aug; 6(8):398-412. PubMed ID: 10969869
[TBL] [Abstract][Full Text] [Related]
18. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature.
Davenport AP
Pharmacol Rev; 2002 Jun; 54(2):219-26. PubMed ID: 12037137
[TBL] [Abstract][Full Text] [Related]
19. Potency of PD155080, an orally active ETA receptor antagonist, determined for human endothelin receptors.
Maguire JJ; Kuc RE; Doherty AM; Davenport AP
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S362-4. PubMed ID: 8587415
[TBL] [Abstract][Full Text] [Related]
20. Coordination of copper(II) ions by the fragments of neuropeptide gamma containing D1, H9, H12 residues and products of copper-catalyzed oxidation.
Jankowska E; Pietruszka M; Kowalik-Jankowska T
Dalton Trans; 2012 Feb; 41(6):1683-94. PubMed ID: 22159001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
